drugset

drugset / Trial / NCT05904236

Safety and Tolerability of Intravenous Administration of ICVB-1042

NCT05904236 ↗

Phase 1 Terminated 17 enrolled IconOVir Bio

NaSingle-groupOpen-labelTreatment

Summary

Study to evaluate the safety and tolerability of intravenous ICVB-1042

Timeline

Start: 2023-06-01
Primary completion: 2024-12-11
Completion: 2024-12-20

Outcome

Outcome not reported

Stopped: “Lack of Demonstrated Clinical Activity”

Publications

Kato Y, Rice N, Pokrass M, Jeong J, Rodriguez R, Field JJ, Nowyhed H. Nonclinical characterization of ICVB-1042 as a selective oncolytic adenovirus for solid tumor treatment. Commun Biol. 2024 Sep 13;7(1):1132. doi: 10.1038/s42003-024-06839-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ICVB-1042	Unknown	—	Intravenous

Indications

No indication recorded.